Granahan Investment Management’s Xeris Biopharma Holdings XERS Stock Holding History

Granahan Investment Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.35M	Sell	921,854 -301,550	-25%	-$2M	0.26%	100
2025 Q4	$9.6M	Buy	1,223,404 +873,236	+249%	+$6.87M	0.41%	63
2025 Q3	$2.85M	Buy	+350,168	New	+$2.33M	0.12%	119
2022 Q2	–	Sell	-405,247	Closed	-$1.04M	–	191
2022 Q1	$1.04M	Sell	405,247 -119,365	-23%	-$292K	0.03%	172
2021 Q4	$1.54M	Buy	524,612 +59,563	+13%	+$129K	0.03%	179
2021 Q3	$1.14M	Buy	465,049 +14,635	+3%	+$42.5K	0.02%	186
2021 Q2	$1.83M	Buy	450,414 +16,704	+4%	+$63.7K	0.03%	180
2021 Q1	$1.96M	Buy	433,710 +121,120	+39%	+$653K	0.04%	172
2020 Q4	$1.54M	Sell	312,590 -33,838	-10%	-$169K	0.03%	180
2020 Q3	$2.05M	Buy	346,428 +6,025	+2%	+$24.1K	0.07%	152
2020 Q2	$905K	Buy	+340,403	New	+$1.19M	0.03%	172
2019 Q1	–	Sell	-82,504	Closed	-$1.4M	–	203
2018 Q4	$1.4M	Sell	82,504 -48,641	-37%	-$976K	0.1%	149
2018 Q3	$2.31M	Buy	131,145 +445	+0.3%	+$9.66K	0.13%	147
2018 Q2	$2.48M	Buy	+130,700	New	+$2.54M	0.15%	150

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Granahan Investment Management's XERS Position: Q1 2026 in Review

Granahan Investment Management reduced its Xeris Biopharma Holdings (XERS) stake by 25% in Q1 2026, selling an estimated $2M and leaving 921,854 shares worth $5.35M. The position accounts for 0.26% of the portfolio, ranked #100.

Granahan Investment Management first reported a position in XERS in Q2 2018 and has held it in 14 quarters since. The position peaked at $9.6M in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Granahan Investment Management held 921,854 shares of Xeris Biopharma Holdings worth $5.35M as of Q1 2026.
Granahan Investment Management sold 301,550 Xeris Biopharma Holdings shares in Q1 2026, an estimated $2M.
Xeris Biopharma Holdings made up 0.26% of Granahan Investment Management's portfolio in Q1 2026, its #100 holding.
Granahan Investment Management first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 14 quarters since.
Granahan Investment Management's Xeris Biopharma Holdings position peaked at $9.6M in Q4 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Granahan Investment Management's 13F filing for Q1 2026, filed 15 May 2026.